{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:44:02Z","timestamp":1790199842073,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,3,25]],"date-time":"2016-03-25T00:00:00Z","timestamp":1458864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA163451"],"award-info":[{"award-number":["R01 CA163451"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 CA186107"],"award-info":[{"award-number":["UM1 CA186107"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA87969"],"award-info":[{"award-number":["P01 CA87969"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 CA176726"],"award-info":[{"award-number":["UM1 CA176726"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2016,7,15]]},"abstract":"<jats:p>Few studies have examined the associations of hypertension and antihypertensive medications with ovarian cancer. In particular, beta\u2010blockers, one of the most commonly prescribed medications to treat hypertension, may reduce ovarian cancer risk by inhibiting beta\u2010adrenergic signaling. We prospectively followed 90,384 women in the Nurses' Health Study (NHS) between 1988\u20132012 and 113,121 NHSII participants between 1989\u20132011. Hypertension and use of antihypertensive medications were self\u2010reported biennially. Cox proportional hazards models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). We documented 948 ovarian cancer cases during follow\u2010up. Similar results were observed in the two cohorts. While hypertension was not associated with ovarian cancer risk (Pooled HR\u2009=\u20091.01; 95% CI\u2009=\u20090.88, 1.16), current use of any antihypertensive medication was associated with slightly increased risk compared to never users (Pooled HR\u2009=\u20091.18; 95% CI: 1.02, 1.37). This increased risk was primarily due to use of thiazide diuretics (Pooled HR\u2009=\u20091.37; 95% CI: 1.13, 1.68). No associations were observed for beta\u2010blockers or angiotensin\u2010converting\u2010enzyme inhibitors. Calcium channel blockers (CCBs) were associated with suggestively reduced risk (NHS HR\u2009=\u20090.73; 95% CI: 0.53, 1.01), after adjusting for all antihypertensive medications. Associations were similar among hypertensive women and stronger for longer use of thiazide diuretics and CCBs. In conclusion, our results provided no evidence that beta\u2010blockers were associated with reduced ovarian cancer risk. In contrast, we observed an increased risk for use of thiazide diuretics that should be confirmed in other studies.<\/jats:p>","DOI":"10.1002\/ijc.30066","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T16:11:24Z","timestamp":1456935084000},"page":"291-299","source":"Crossref","is-referenced-by-count":32,"title":["Hypertension, use of antihypertensive medications, and risk of epithelial ovarian cancer"],"prefix":"10.1002","volume":"139","author":[{"given":"Tianyi","family":"Huang","sequence":"first","affiliation":[{"name":"Channing Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"},{"name":"Department of Epidemiology Harvard T.H. Chan School of Public Health Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Poole","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Heather","family":"Eliassen","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"},{"name":"Department of Epidemiology Harvard T.H. Chan School of Public Health Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia I.","family":"Okereke","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"},{"name":"Department of Epidemiology Harvard T.H. Chan School of Public Health Boston MA"},{"name":"Department of Psychiatry Brigham and Women's Hospital and Harvard Medical School Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura D.","family":"Kubzansky","sequence":"additional","affiliation":[{"name":"Department of Social and Behavioral Sciences Harvard T.H. Chan School of Public Health Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology MD Anderson Cancer Center Houston TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Forman","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"},{"name":"Renal Division, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley S.","family":"Tworoger","sequence":"additional","affiliation":[{"name":"Channing Division of Network Medicine, Department of Medicine Brigham and Women's Hospital and Harvard Medical School Boston MA"},{"name":"Department of Epidemiology Harvard T.H. Chan School of Public Health Boston MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70260-6"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2729"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70106-6"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05704-X"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt372"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djt374"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.110.168005"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.542290"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1698"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1447"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.07.102"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29392"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-85"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.03.007"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.34.2.320"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyr130"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwj128"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114319"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.108.117630"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.27.5.1065"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2307\/2532940"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-1183-T"},{"key":"e_1_2_6_25_1","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/ALN.0b013e3181e73eea","article-title":"Variations in pharmacology of beta\u2010blockers may contribute to heterogeneous results in trials of perioperative beta\u2010blockade","volume":"113","author":"Badgett RG","year":"2010","journal-title":"Anesthesiology"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10368"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2012.04.001"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197908093010602"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg341"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d8190"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:CARD.0000015855.02485.e3"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/2001-1326-1-16"},{"key":"e_1_2_6_33_1","article-title":"Serum uric acid increases risk of cancer incidence and mortality: a systematic review and meta\u2010analysis","author":"Yan S","year":"2014","journal-title":"Med Inflamm"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/CEJ.0b013e328313631a"},{"key":"e_1_2_6_35_1","article-title":"Increased risk of cancer in relation to gout: a review of three prospective cohort studies with 50,358 subjects","author":"Wang W","year":"2014","journal-title":"Med Inflamm"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi879"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0019901"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-10-1180"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwt098"},{"key":"e_1_2_6_40_1","first-page":"539","article-title":"Report of Medical Research Council Working Party on Mild to Moderate Hypertension","volume":"2","author":"Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension.","year":"1981","journal-title":"Lancet"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-93-6-817"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.30066","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.30066","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.30066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T00:34:01Z","timestamp":1694306041000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.30066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,25]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,7,15]]}},"alternative-id":["10.1002\/ijc.30066"],"URL":"https:\/\/doi.org\/10.1002\/ijc.30066","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,25]]}}}